About the efficacy and safety of radium-223 plus enzalutamide/enzalutamide in mCRPC

The combination of radium-223 (Xofigo) and enzalutamide/enzalutamide has shown positive efficacy and safety in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Based on recent data from the Phase 3 PEACE-3 trial, this combined effect is not only statistically significant but also clinically important.

In the trial, the addition of radium-223 resulted in a significant improvement in radiographic progression-free survival (rPFS) and a 31% reduction in the risk of progression or death compared with enzalutamide alone (HR, 0.69; 95% CI, 0.54-0.87; P=0.0009). This suggests that radium-223 offers a new strategy for treating mCRPC patients beyond traditional androgen receptor antagonist (ARPI) monotherapy. This data is not only exciting for clinicians, but also brings new hope to patients.

As the main person in charge of this study, he pointed out that the importance of this discovery is that it provides a new perspective for the treatment of mCRPC patients. With the continuous in-depth research on cancer treatment in recent years, traditional single therapy has gradually been replaced by combination therapy, which can not only improve the efficacy but also reduce the risk of adverse reactions. Saad emphasized that the combination of radium-223 and enzalutamide showed superior survival data, especially in patients with obvious bone metastases.

In addition to the improvement in rPFS, preliminary results also show that the combination also has encouraging performance in overall survival (OS), with a 31% reduction in the risk of death. Although the final statistical significance of this endpoint has not yet been fully determined, demonstration in this direction will undoubtedly drive further research. More importantly, this combination has a good safety profile. Most patients can complete the full 6 cycles of radium-223 treatment with almost no unexpected adverse reactions.

In terms of bone health,The PEACE-3 trial also provides the latest research data related to bone health agents (BHAs). Long-term follow-up results show that early initiation of BHAs is not only associated with improvements in rPFS and OS, but may also play an important role in delaying bone-related complications. This finding emphasizes that BHAs should be integrated as early as possible in the treatment of mCRPC patients to improve patient survival and quality of life.

RadiumThe combination of -223 with enzalutamide provides a new treatment option and brings new hope to mCRPC patients. As this combination therapy is further studied, more data may be available to support this treatment strategy in the future. Clinicians and researchers should continue to monitor advances in this area in order to provide patients with the best treatment options.

In future clinical practice, patient care will become particularly important. Taking into account the pathological characteristics of mCRPC patients and their responses to different treatments, doctors should comprehensively consider the patient's specific situation and choose the most appropriate treatment plan when formulating a treatment plan. In addition, regular monitoring of patients to evaluate efficacy and adverse reactions will help optimize the treatment process.

With the rapid development of biomedical technology, treatments for mCRPC are also constantly enriched. The combined application of radium-223 and enzalutamide is just one of them. In the future, more new drugs and new combinations may enter clinical practice to further improve the survival rate and quality of life of mCRPC patients. Therefore, continuing large-scale, multi-center clinical trials will be key to evaluating the effectiveness and safety of these new treatments.

References:https://www.onclive.com/view/dr-saad-on-the-efficacy-and-safety-of-radium-223-plus-enzalutamide-in-mcrpc